New pharmaceutical forms for administration of medicaments by oral route, with programmed release

Claim 2

A pharmaceutical form of medicaments for oral administration with selectively adjustable programmed release and controlled absorption, comprising at least one of: (a) granulated highly compressed pulverized particles obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 2 mm, of at least one active ingredient with an active excipient containing a physiologically active neutralization agent for controlling the pH; (b) granulated highly compressed pulverized particles obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 2 mm, containing at least one active ingredient, coated with excipients determining the slow penetration of the digestive and alimentary liquids; and (c) granulated highly compressed pulverized particles containing at least one active ingredient obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 2 mm, coated with a very thin layer of lipids present at a rate of 5 to 30% in relation to the active ingredient(s), the relative proportion of each of these types of particles (a), (b) and (c) varying from 0 to 100% according to the desired absorption curve of the medicament associated with said pharmaceutical form; wherein said active ingredients is selected from the group consisting of diazepam, cephalexin, cimetidin, cephalotin, methyldopa, cephazolin, propranolol, indomethacin, ibuprofen, doxycyclin, amoxycillin, furosemide, dipyridamole, spironolactone, erythromycin, gentamicin, diclofenac, glibenclamide, althiaside, naproxen, propoxyphene, allopurinol, sulfamethoxazole, ampicillin, prosultiame, lincomycin, betamethasone, troleandomycin, vincamine, clonidine, glafenine, clometacine, disopyramide, sulpiride, oxyphenbutazone, clorazepate, cephalosporin, rifamycin, sulindac and vincamine hydrochlorate.

Claim 3

A pharmaceutical form according to claim 1, wherein the compression is carried out at a pressure of about 15 tons.

Claim 4

A pharmaceutical form according to claim 1, wherein the size of the particles is between 0.5 and 1.0 mm in diameter.

Claim 5

A pharmaceutical form according to claim 1, wherein the excipient of type (a) further comprises one or two substances chosen from the group consisting of polyvinylpyrrolidone, cellulose, ethylcellulose, methacrylates, acetophthalates and shellac.

Claim 6

A pharmaceutical form according to claim 1, wherein the pH control agent is chosen from the pharmaceutically acceptable organic acids soluble in at least one of alcohol, chloroform, ether, acetone and water, when it is desired to lower the pH value at the moment of discharge of the medicament, or from at least one of the alkaline carbonates and bicarbonates, the alkaline salts of pharmaceutically acceptable weak organic acids and the pharmaceutically compatible organic bases soluble in at least one of alcohol and water, when it is desired to raise the pH value during discharge of the medicament, providing that the pH control agent is soluble in the same solvent as the active ingredient(s).

Claim 7

A pharmaceutical form according to claim 16, wherein the excipient separating the layers which contain the medicament, for particles of type (a), or coating the particles of type (b), or mixed with the active ingredient(s) for the particles of type (c), is also composed of one or two substances chosen from the group consisting of polyvinylpyrrolidone, cellulose, ethylcellulose, methacrylates, acetophthalates and shellac.

Claim 8

A pharmaceutical form according to claim 1, wherein the pharmaceutically acceptable lipid coating the particles of type (c), is soluble in the same solvent as the active ingredient(s).

Claim 9

A pharmaceutical form according to claim 1, wherein the pH control agent is composed of a mixture of several pharmaceutically compatible organic acids having different solubilities.

Claim 10

A pharmaceutical form in accordance with claim 8, wherein the mixture of organic acids is composed of at least one of fumaric acid, tartaric acid and citric acid.

Claim 11

A pharmaceutical form according to claim 8, wherein the amount of acid which forms the pH control agent, in relation to the amount of the active ingredient, decreases from the central core to the periphery of the particle which thus forms a particle with a pH gradient.

Claim 12

A pharmaceutical form according to claim 10, wherein the acid/active ingredient ratio varies from 1.5 to 5/1 (central core) to 0.2-0.5/1 (peripheral layer).

Claim 13

A pharmaceutical from according to claim 1, wherein the particles contain at least one of glucose and derivatives thereof.

Claim 14

A pharmaceutical form according to claim 12, wherein the amount of said at least one of glucose and derivatives thereof is between 1 and 6% by weight.

Claim 15

A process for preparing a pharmaceutical form according to claim 1 comprising, preparing at least one of particles (a), (b) and (c) comprising the steps of: (A) (1) type (a) (with controlled pH): mixing the active ingredient(s) with a disintegrator when required, granulating this mixture with a pH control agent solution in a proportion of 0.05 to 1% with respect to the active ingredient, granulating with the chosen excipients, treating the wet granulate obtained in an oscillating granulator, drying the granules at a temperature between 30 and 45° C., compressing at a pressure equal to or greater than 10 tons, grinding, sifting and collecting the particles whose size is between 0.2 and 2.0 mm in diameter, the finest and coarsest particles being recycled, and by coating with the chosen excipients; (2) type (b) (compressed miniaturized granules): mixing the active ingredient(s) with a disintegrator when required, granulating this mixture with the chosen excipient, treating the wet granulate in an oscillating granulator, drying the granules at a temperature between 30 and 45° C., compressing at a pressure equal to or greater than 10 tons, grinding and sifting the compressed material and collecting the particles whose size is between 0.2 and 2.0 mm in diameter, the finest and coarsest particles being recycled, and coating with the chosen excipient; (3) type (c) (miniaturized lipidized granules): mixing the active ingredient(s) with a disintegrator when required, granulating this mixture with a solution of lipids, the proportion of lipids added varying between 5 and 25% by weight of the active ingredient, mixing with a solution containing the chosen excipient, treating the wet granulate in an oscillating granulator, drying the granules at a temperature between 30 and 45° C., compressing at a pressure equal to or greater than 10 tons, grinding and sifting the compressed material and collecting the particles whose size is between 0.2 and 2.0 mm in diameter, the finest and coarsest particles being recycled, and coating with chosen excipient; (B) mixing particles (a), (b) and (c) in a desired proportion.

Claim 16

A pharmaceutical form according to claim 1 wherein granules defined under (a), (b) and (c) are all present.

Claim 17

A pharmaceutical form of claim 1, wherein said particles (a) comprise a central core surrounded by several layers containing a mixture of one or more active ingredients with an active excipient containing a physiologically active neutralization agent for controlling the pH, the layers containing the active ingredients being separated from each other by layers of excipient which determine the slow penetration of the digestive and alimentary liquids.

Claim 18

In a pharmaceutical form of medicaments for oral administration with selectively adjustable programmed release and controlled absorption, the improvement comprising at least one of: (a) granulated highly compressed pulverized particles obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 2 mm, of at least one active ingredient with an active excipient containing a physiologically active neutralization agent for controlling the pH; (b) granulated highly compressed pulverized particles obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 1 mm, containing at least one active ingredient coated with excipients determining the slow penetration of the digestive and alimentary liquids; and (c) granulated highly compressed pulverized particles containing at least one active ingredient, obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 2 mm, coated with a very thin layer of lipids present at a rate of 5 to 30% in relation to the active ingredient(s), the relative proportion of each of these types of particles (a), (b) and (c) varying from 0 to 100% according to the desired absorption curve of the medicament associated with said pharmaceutical form; wherein said active ingredient is selected from the group consisting of diazepam, cephalexin, cimetidin, cephalotin, methyldopa, cephazolin, propranolol, indomethacin, ibuprofen, doxycyclin, amoxycillin, furosemide, dipyridamole, spironolactone, erythromycin, gentamicin, diclofenac, glibenclamide, althiaside, naproxen, propoxyphene, allopurinol, sulfamethoxazole, ampicillin, prosultiame, lincomycin, betamethasone, troleandomycin, vincamine, clonidine, glafenine, clometacine, disopyramide, sulpiride, oxyphenbutazone, clorazepate, cephalosporin, rifamycin, sulindac and vincamine hydrochlorate.

Claim 19

In a pharmaceutical form of medicaments for oral administration with selectively adjustable programmed release and controlled absorption, the improvement comprising at least one of: (a) granulated highly compressed pulverized particles obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 2 mm, of at least one active ingredient with an active excipient containing a physiologically active neutralization agent for controlling the pH; (b) granulated highly compressed pulverized particles obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 1 mm, containing at least one active ingredient coated with excipients determining the slow penetration of the digestive and alimentary liquids; and (c) granulated highly compressed pulverized particles containing at least one active ingredient, obtained by high to very high compression at a pressure equal to or greater than 10 tons and thereafter grinding to produce said particles having a diameter between 0.2 and 2 mm, coated with a very thin layer of lipids present at a rate of 5 to 30% in relation to the active ingredient(s), the relative proportion of each of these types of particles (a), (b) and (c) varying from 0 to 100% according to the desired absorption curve of the medicament associated with said pharmaceutical form; wherein said active ingredient is selected from the group consisting of diazepam, cephalexin, cimetidin, cephalotin, methyldopa, cephazolin, propranolol, indomethacin, ibuprofen, doxycyclin, amoxycillin, furosemide, dipyridamole, spironolactone, erythromycin, gentamicin, diclofenac, glibenclamide, althiaside, naproxen, propoxyphene, allopurinol, sulfamethoxazole, ampicillin, prosultiame, lincomycin, betamethasone, troleandomycin, vincamine, clonidine, glafenine, clometacine, disopyramide, sulpiride, oxyphenbutazone, clorazepate, cephalosporin, rifamycin, sulindac and vincamine hydrochlorate.

Claim 20

The improvement of claim 17, wherein the excipient of type (a) further comprises one or two substances chosen from the group consisting of polyvinyl-pyrrolidone, cellulose, ethylcellulose, methacrylates, acetophthalates and shellac.

Claim 21

The improvement of claim 17, wherein the pH control agent is chosen from the pharmaceutically acceptable organic acids soluble in at least one of alcohol, chloroform, ether, acetone, and water, when it is desired to lower the pH value at the moment of discharge of the medicament, or from at least one of the alkaline carbonates and bicarbonates, the alkaline salts of pharmaceutically acceptable weak organic acids and the pharmaceutically compatible organic bases soluble in at least one of alcohol and water, when it is desired to raise the pH value during discharge of the medicament, providing that the pH control agent is soluble in the same solvent as the active ingredient(s).

Claim 22

The improvement of claim 17, wherein said particles (a) comprise a central core surrounded by several layers containing a mixture of one or more active ingredients with an active excipient containing a physiologically active neutralization agent for controlling the pH, the layers containing the active ingredients being separated from each other by layers of excipient which determine the slow penetration of the digestive and alimentary liquids.